Eli Lilly launches home delivery of obesity drug Zepbound — but warns against its use for cosmetic weight loss

Eli Lilly & Co. on Thursday announced the launch of new digital health services that could help smooth patient access to the obesity drug Zepbound and other medications — but also warned against the use of some of its most-popular drugs for cosmetic weight loss.

Previous post Cannabis stocks mark second day of gains as DEA confirms its review of marijuana’s Schedule I classification
Next post State lawmakers are revving up AI bills after quarter-century of inaction on tech by Congress